2 unknown, 1 active not recruiting, 1 completed. 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Unknown 2, Active not recruiting 1, Completed 1 |
Follow Allyx Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Evaluating the Potential of BMS-984923 to Alter the Systemic Exposure of Three Orally Administered Probe Substrates BMS-984923, Midazolam, Caffeine - Drug Drug Interaction (DDI) | Phase 1 | Active not recruiting | Allyx Therapeutics | 36 | 2024-11-04 | 2025-02-07 |
| A Study to Assess the Safety of BMS-984923 Compared to Placebo, in People With Parkinson's BMS-9894923 - Parkinson Disease | Phase 1 | Unknown | Allyx Therapeutics | 18 | 2024-03-15 | 2024-03-18 |
| A Multiple Ascending Dose Study in Healthy Volunteers and Patients With Alzheimer's Disease BMS-984923, Placebo - Alzheimer's Disease | Phase 1 | Completed | Allyx Therapeutics | 51 | 2023-03-28 | 2025-11-06 |
| Food Effect Study of BMS-984923 in Healthy Older Adult Volunteers BMS-984923 - Alzheimer Disease, Dementia | Phase 1 | Unknown | Allyx Therapeutics | 12 | 2023-01-10 | 2024-07-30 |
Alzheimer Disease (3) · Dementia (1) · Parkinson Disease (1)
Caffeine (1) · Dextromethorphan (1) · Exercise (1) · Midazolam (1)
United States (4)
Stephanie Post, MD (2) · Adam Mecca, MD, PhD (1) · Laurie Sanders, Ph.D (1)
R01AG073177 (1), SB1AG087748 (1)